TMS Co

TMS Co R&D per Employee

The R&D Spending per Employee of TMS Co (4891.T) as of Nov 6, 2026 is 39.15 M JPY. In the previous year, R&D Spending per Employee was 44.36 M JPY — a change of -11.76% (lower).

R&D per Employee

39.15 MJPY

YoY

-11.76%

Last updated:

R&D Spending per Employee of TMS Co is 2026 39.15 M JPY. R&D Spending per Employee of TMS Co was 2025 44.36 M JPY. It decreases by -11.76% lower compared to the previous year.

The TMS Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2021
43.09 M JPY
Jan 1, 2022
7.37 M JPY
Jan 1, 2023
20.91 M JPY
Jan 1, 2024
43.41 M JPY
Jan 1, 2025
44.36 M JPY
Jan 1, 2026
39.15 M JPY
The TMS Co R&D per Employee history
YEARR&D per EmployeeYoY
39.15 MJPY-11.76%
44.36 MJPY+2.20%
43.41 MJPY+107.59%
20.91 MJPY+183.93%
7.37 MJPY-82.91%
43.09 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

R&D Spending per Employee of TMS Co is 39.15 M JPY in 2026.

R&D Spending per Employee of TMS Co changed from 44.36 M JPY to 39.15 M JPY, representing a -11.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee TMS Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TMS Co

All Key Metrics — TMS Co